Mycophenolate mofetil in the treatment of retroperitoneal fibrosis

Fareeha Khalil; M. A. Mir; Rocco C. Venuto

doi:10.1007/s10067-007-0826-4

Mycophenolate mofetil in the treatment of retroperitoneal fibrosis

Fareeha Khalil, M. A. Mir, Rocco C. Venuto

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.

Original language	English (US)
Pages (from-to)	679-681
Number of pages	3
Journal	Clinical Rheumatology
Volume	27
Issue number	5
DOIs	https://doi.org/10.1007/s10067-007-0826-4
State	Published - May 2008

All Science Journal Classification (ASJC) codes

Rheumatology

Access to Document

10.1007/s10067-007-0826-4

Cite this

@article{cb393529b64340d5b2fe55b71e4767d6,

title = "Mycophenolate mofetil in the treatment of retroperitoneal fibrosis",

abstract = "The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.",

author = "Fareeha Khalil and Mir, {M. A.} and Venuto, {Rocco C.}",

year = "2008",

month = may,

doi = "10.1007/s10067-007-0826-4",

language = "English (US)",

volume = "27",

pages = "679--681",

journal = "Clinical Rheumatology",

issn = "0770-3198",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Mycophenolate mofetil in the treatment of retroperitoneal fibrosis

AU - Khalil, Fareeha

AU - Mir, M. A.

AU - Venuto, Rocco C.

PY - 2008/5

Y1 - 2008/5

N2 - The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.

AB - The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.

UR - http://www.scopus.com/inward/record.url?scp=41849118449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849118449&partnerID=8YFLogxK

U2 - 10.1007/s10067-007-0826-4

DO - 10.1007/s10067-007-0826-4

M3 - Article

C2 - 18185904

AN - SCOPUS:41849118449

SN - 0770-3198

VL - 27

SP - 679

EP - 681

JO - Clinical Rheumatology

JF - Clinical Rheumatology

IS - 5

ER -

Mycophenolate mofetil in the treatment of retroperitoneal fibrosis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this